ArticleHeart rhythm O22026
Evolving modalities of atrial fibrillation ablation: From thermal to nonthermal.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review topic provides an overview of a novel technique for catheter ablation in patients with atrial fibrillation (AF) called pulsed field ablation. Pulsed field ablation uses a nonthermal vs thermal approach (radiofrequency or cryoablation) for obtaining myocardial cell death, which is referred to as irreversible electroporation for the treatment of AF via pulmonary vein isolation. This emerging technology delivers microsecond high-voltage electrical fields that may limit damage to tissues outside the myocardium and offers a promising approach to managing AF with shorter procedural times and fewer major complications. This review aimed to educate allied health professionals regarding this evolving technology by summarizing the biophysics of irreversible electroporation, clinical evidence supporting pulse field ablation, associated complications, and future applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.